Showing results (311-320 of 357) with videos related to
Sort By:
Pageof 36
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 1, 1992
Pseudo-gamma heavy chain (IgG4 lambda) deposition diseaseR R Tubbs, V Berkley, R Valenzuela, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2006
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinomaT K Choueiri, Bi Rini, J A Garcia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findingsR M Bukowski, T Olencki, H Gunn, et al.Journal of Developmental and Behavioral Pediatrics : JDBP|June 30, 2016
Social Competence in Childhood Brain Tumor Survivors: Feasibility and Preliminary Outcomes of a Peer-Mediated InterventionKatie A Devine, William M Bukowski, Olle Jane Z Sahler, et al.The Journal of Urology|September 18, 2007
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941Bernard Escudier, Toni K Choueiri, Stéphane Oudard, et al.The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyAli Reza Golshayan, Saby George, Daniel Y Heng, et al.AJR. American Journal of Roentgenology|November 1, 1985
Magnetic resonance with marked T2-weighted images: improved demonstration of brain lesions, tumor, and edemaA S Smith, M A Weinstein, M T Modic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinomaChristopher J Herrem, Tomohide Tatsumi, Kathleen S Olson, et al.Pageof 36